Cardio Diagnostics Holdings, Inc has launched PrecisionCHD™, a blood-based detection test for coronary heart disease (CHD) that integrates epigenetic and genetic biomarkers with artificial intelligence. The test is the only detection technology that combines these elements and offers remote and scalable deployment capabilities across the US. It requires only a simple blood sample, making it far more accessible than current imaging-based CHD tests, which expose patients to radiation and require advanced healthcare infrastructure. PrecisionCHD™ provides results within 10 business days of testing. Cardio Diagnostics' proprietary Actionable Clinical Intelligence platform enhances the product by providing clinicians with novel data-driven insights in an easily comprehensible format.
Cardiovascular disease is responsible for significant human and economic burden in the US. Despite this, many rural and underserved communities lack access to specialist care or advanced medical equipment, limiting their ability to detect CHD early on. PrecisionCHD™ seeks to democratise access to cutting-edge heart disease detection technologies by empowering primary care clinicians across the country.
Keywords: Cardio Diagnostics Holdings, Inc; PrecisionCHD™; coronary heart disease